Altimmune, Inc. (FRA:3G0)

Germany flag Germany · Delayed Price · Currency is EUR
4.451
+0.178 (4.17%)
Last updated: Dec 5, 2025, 8:10 AM CET
-46.73%
Market Cap 475.10M
Revenue (ttm) 17.05K
Net Income (ttm) -71.52M
Shares Out n/a
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 260
Open 4.451
Previous Close 4.273
Day's Range 4.451 - 4.451
52-Week Range 2.320 - 10.118
Beta n/a
RSI 62.23
Earnings Date Feb 26, 2026

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3G0
Full Company Profile

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.